Table 2. DLTs and MTD.

Cohort	N	LY2603618 dose (mg/m2)	DLTs (n)
1	3	40a	0
2	3	40b	0
3	3	70	0
4	13c	105	G3 diarrhea (1)
5	6	150	G4 allergic reaction/hypersensitivity (1)
6	3	195	G3 lower GI hemorrhage (1)d;
			G3 fatigue (1);
			G4 thrombocytopenia (2)e

^aCohort 1 received 40 mg/m² over a 4.5-hour period, based on PK modeling of preclinical data determining the BED

^bCohort 2 received 40 mg/m² over a 1-hour period, a duration selected based on PK exposure data for Cohort 1

^cStudy was amended to expand patient accrual to the 105 mg/m² dose to evaluate the PK parameters and to provide guidance on the determination of a biological dose relative to the MTD

^dLater determined to be unrelated to LY2603618

^ePlatelet count <25,000 cells/m²